On September 27, 2016, the Substance Abuse and Mental Health Services Administration (SAMHSA) published a final rule establishing annual reporting requirements for certain practitioners who prescribe buprenorphine-based medication-assisted treatment for opioid disorders under the Controlled Substances Act. As previously reported, SAMHSA published a rule on July 8, 2016 that expanded from 100 to 275 the number of patients that qualified practitioners may treat with buprenorphine. The September 27 rule requires practitioners approved to treat additional patients to submit annually to SAMHSA information about their practice, such as caseload and diversion control plan information, for purposes of monitoring regulatory compliance with the July 8 rule. The rule is effective on October 27, 2016.
This article is presented for informational purposes only and is not intended to constitute legal advice.
